PORTSMOUTH — Lonza Biologics has begun what it describes as “small-scale” production of the COVID-19 vaccine from Moderna while the drug is in its phase 3 clinical trial.

Lonza spokesperson Glenn Myers confirmed “we have started small-scale manufacturing,” but he couldn’t divulge how much volume the company at Pease International Tradeport was producing at this point.

He added that “each large-scale line will be able to produce around 100 million doses a year, based on a dosage of 100ug. The final dose will be confirmed at the end of the phase 3 clinical trial.” (In medical terms, UG is one microgram.)

Of the some 1,000 employees at the Pease plant, according to Myers, 50 employees are dedicated full-time to the production initiative of the vaccine that Moderna has labeled mRNA-1273.


Granite State News Collaborative

These articles are being shared by partners in The Granite State News Collaborative. For more information visit collaborativenh.org

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.